2022Mar29 — Apeiron Therapeutics
Summary
In conjunction with the financing, James Huang, Founding Managing Partner at Panacea Venture joined the Apeiron Board of Directors.Apeiron, in collaboration with Exscientia (NASDAQ: EXAI), is developing a pipeline of novel CDK therapies. Its leading asset, GTAEXS617, an orally bioavailable, highly potent and selective small-molecule inhibitor of CDK7, is currently in IND-enabling studies and pre-clinical data will be presented at this years AACR.Apeiron also announced a strategic partnership with Viva Biotech (HK: 01873) under which Viva Biotech provides world-leading structure-based drug discovery expertise to enhance Apeirons AI-empowered innovative drug discovery and development platform.We are excited to welcome a group of visionary investors, embracing our journey and mission to deliver breakthrough therapies to cancer patients globally, said Dr. Mingxi Li, Co-Founder and CEO of Apeiron, Over the past two years, our team has built a unique pipeline of precision oncology therapies, focusing on CDKs and synthetic lethality. We will continue strengthen our integrated drug discovery platform with AI and structural biology.Apeiron is strategically based in Shanghai and in the San Francisco Bay Area, with significant collaborations in the UK enabling us to tap into technologies and talent from all three continents. Our team and partners bring together deep expertise in oncology and drug discovery to enable efficient and scalable discovery and development of novel drugs.Panacea Venture is a healthcare focused venture capital firm, with offices in Shanghai, Hong Kong, and Silicon Valley. At the same time, we focus on finding and investing in high potential biotech start-ups, solve unmet clinical medical needs in the form of EFS (service for equity), and continue to build an open cooperation platform and win-win ecosystem for biotech innovation.